Market Research Logo

Global Benign Prostatic Hyperplasia (BPH) Drugs Market 2017-2021

Global Benign Prostatic Hyperplasia (BPH) Drugs Market 2017-2021

About Benign Prostatic Hyperplasia Drugs

Urology is a branch of medicine that deals with the health of the urinary tract and reproductive tract in men and women. Urologic diseases or conditions include infection in the urinary tract, bladder control problems, kidney stones and prostate problems, among others. The prostate gland surrounds the urethra, the tube that carries urine from the bladder out of the body. Benign prostatic hyperplasia (BPH) is an enlarged prostate, which increases the size of the prostate gland. As the prostate gets enlarged, it may squeeze or partly block the urethra, resulting in significantly blocking urine flow. BPH is normal in the aging process of a male, caused by changes in hormone balance and cell-growth.

Technavio’s analysts forecast the global benign prostatic hyperplasia drugs market to grow at a CAGR of 7.07% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global benign prostatic hyperplasia drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Benign Prostatic Hyperplasia Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Astellas Pharma
  • Eli Lilly
  • GlaxoSmithKline
  • Sanofi
Other prominent vendors
  • ADC Therapeutics
  • Advaxis
  • Agennix
  • ANI Pharmaceuticals
  • Bayer HealthCare
  • BHR Pharma
  • Bristol-Myers Squibb
  • Boehringer Ingelheim
  • Dendreon (Valeant Pharmaceuticals)
  • Eisai
  • Endo Pharmaceuticals
  • Ferring
  • Foresee Pharmaceuticals
  • Io Therapeutics
  • LIDDS
  • Madrigal Pharmaceuticals
  • Merck
  • Novartis
  • Nymox Pharmaceutical
  • Spectrum Pharmaceuticals
  • Takeda Pharmaceuticals
  • Teva Pharmaceutical Industries
  • Urologix
Market driver
  • Growing geriatric male population.
  • For a full, detailed list, view our report
Market challenge
  • Availability of minimally invasive surgery as a drug replacement.
  • For a full, detailed list, view our report
Market trend
  • Advancements in early-stage diagnosis through new diagnostic methods.
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Benign Prostatic Hyperplasia Drugs Market 2017-2021

Technavio recognizes the following companies as the key players in the global benign prostatic hyperplasia drugs market: Astellas Pharma, Eli Lilly, GlaxoSmithKline, and Sanofi.

Other Prominent Vendors in the market are: ADC Therapeutics, Advaxis, Agennix, ANI Pharmaceuticals, Bayer HealthCare, BHR Pharma, Bristol-Myers Squibb, Boehringer Ingelheim, Dendreo (Valeant Pharmaceuticals), Eisai, Endo Pharmaceuticals, Ferring, Foresee Pharmaceuticals, Io Therapeutics, LIDDS, Madrigal Pharmaceuticals, Merck, Novartis, Nymox Pharmaceutical, Spectrum Pharmaceuticals, Takeda Pharmaceuticals, Teva Pharmaceutical Industries, and Urologix.

Commenting on the report, an analyst from Technavio’s team said: “One trend in market is advancements in early-stage diagnosis through new diagnostic methods. New diagnostic methods for BPH are likely to boost the diagnosed patient pool, thereby fueling the market growth. The market has seen the emergence of novel diagnostic tests, which are expected to be more accurate than the conventional PSA blood test. Considering the failure of PSA test to detect early-stage BPH, researchers have been working on new diagnostic methods to improve diagnosis.”

According to the report, one driver in market is growing geriatric male population. The presence of a large population with BPH symptoms is expected to drive the market growth. The risk of BPH increases exponentially with the rise in the age of an individual. Approximately, 80% of men who reach 60 years and above have mild to strong symptoms of BPH. This disorder affects one in 38 individuals in the age group of 40-59 years; however, in the age group of 60-69 years, it affects one in 14 individuals. However, the chances of developing this disorder among the population of under 40 years are rare. This indicates that rising aging male population is directly proportional to the risk of BPH. Currently, out of the total older population in the world, those aged above 65 years are the fastest-growing population group, accounting for 8.1% of the total population in 2014. This group is expected to reach 16% by 2050. This scenario is expected to drive the market growth.

Further, the report states that one challenges in market is availability of minimally invasive surgery as a drug replacement. The growing popularity of minimally invasive surgeries as an alternative to the drug to cure BPH could hinder the market growth. The minimally invasive alternatives such as laser surgeries, transurethral microwave thermotherapy (TUMT), transurethral needle ablation (TUNA), and open or laparoscopic subtotal prostatectomy require less recovery time with a minimum hospital stay. Since the maximum number of individuals are diagnosed at the chronic stages, the physicians prefer surgeries, which helps treat the indication effectively. Further, laparoscopic surgeries and robotic surgeries are gaining traction in the market, as they offer individuals a quicker and comfortable recovery option. In addition, transurethral resection of the prostate (TURP) is one of the most common treatment approaches for enlarged prostate in which resectoscope equipped with small cutting tools is inserted into the urethra to remove blocking cells, thereby relieving the individual from BPH symptoms.

Companies Mentioned

Astellas Pharma, Eli Lilly, GlaxoSmithKline, Sanofi, ADC Therapeutics, Advaxis, Agennix, ANI Pharmaceuticals, Bayer HealthCare, BHR Pharma, Bristol-Myers Squibb, Boehringer Ingelheim, Dendreo (Valeant Pharmaceuticals), Eisai, Endo Pharmaceuticals, Ferring, Foresee Pharmaceuticals, Io Therapeutics, LIDDS, Madrigal Pharmaceuticals, Merck, Novartis, Nymox Pharmaceutical, Spectrum Pharmaceuticals, Takeda Pharmaceuticals, Teva Pharmaceutical Industries, and Urologix.

  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Market outline
      • Table Risk factors of prostate gland enlargement
      • Table Difference between prostate cancer and BPH
  • BPH diagnostics
    • Overview
  • Pipeline landscape
    • Table Pipeline analysis
    • Table Pipeline landscape
  • Market landscape
    • Market overview
      • Table Global BPH drugs market snapshot
      • Table Global BPH drugs market 2016-2021 ($ millions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by MOA
    • Table Market segmentation by MOA 2016
    • Alpha-blockers
      • Table Global BPH alpha-blockers drugs market 2016-2021 ($ millions)
    • 5-ARIs
      • Table Global BPH 5-ARIs drugs market 2016-2021 ($ millions)
    • PDE-5 inhibitors
      • Table Global BPH PDE-5 inhibitors drugs market 2016-2021 ($ millions)
    • Others
  • Geographical segmentation
    • Table Segmentation of global BPH drugs market based on geography 2016 and 2021 (%)
    • Table Global BPH drugs market revenue by geography 2016-2021 ($ millions)
    • BPH drugs market in Americas
      • Table Market scenario in Americas
      • Table BPH drugs market in Americas 2016-2021 ($ millions)
    • BPH drugs market in EMEA
      • Table Market scenario in EMEA
      • Table BPH drugs market in EMEA 2016-2021 ($ millions)
    • BPH drugs market in APAC
      • Table Market scenario in APAC
      • Table BPH drugs market in APAC 2016-2021 ($ millions)
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Percentage of potential population for BPH among people with 65+ years 2014 and 2050
    • Market challenges
      • Table Prominent side effects of BPH medication
      • Table Impact of patent loss on AVODART 2014-2015 (GBP millions)
  • Market trends
    • Advancements in early-stage diagnosis through new diagnostic methods
      • Table New advancements in diagnosis of BPH
    • Growing demand for MRI and ultrasound-guided prostate biopsy procedures
    • Growing focus toward new MOA
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global BPH drugs market 2016
      • Table Competitive analysis of global BPH drugs market
  • Key vendor analysis
    • Astellas Pharma
      • Table Astellas Pharma: Strength assessment
      • Table Astellas Pharma: Strategy assessment
      • Table Astellas Pharma: Opportunity assessment
    • Eli Lilly
      • Table Eli Lilly: Key highlights
      • Table Eli Lilly: Strength assessment
      • Table Eli Lilly: Strategy assessment
      • Table Eli Lilly: Opportunity assessment
    • GlaxoSmithKline
      • Table GlaxoSmithKline: Strength assessment
      • Table GlaxoSmithKline: Strategy assessment
      • Table GlaxoSmithKline: Opportunity assessment
    • Sanofi
      • Table Sanofi: Key highlights
      • Table Sanofi: Strength assessment
      • Table Sanofi: Strategy assessment
      • Table Sanofi: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report